Targeting NK-cell checkpoints for cancer immunotherapy
Muntasell A (1), Ochoa MC (2), Cordeiro L (2), Berraondo P (1), López-Díaz de Cerio A (3), Cabo M (1), López-Botet M (1), Melero I (4).
(1) Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
(2) Centro de Investigacion Medica Aplicada (CIMA), Pamplona, Spain.
(3) Departamento de Inmunologia e Inmunoterapia, Clinica Universidad de Navarra, Pamplona, Spain.
(4) Centro de Investigacion Medica Aplicada (CIMA), Pamplona, Spain; Departamento de Inmunologia e Inmunoterapia, Clinica Universidad de Navarra, Pamplona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain.
Magazine: Current Opinion in Immunology
Date: Feb 22, 2017Immunology [SP]
Natural Killer (NK) cells are cytotoxic lymphocytes specialized in early defense against virus-infected and transformed cells. NK-cell function is regulated by activating and inhibitory surface receptors recognizing their ligands on transformed cells. Modulation of NK numbers and/or function by a variety of agents such as cytokines and monoclonal antibodies may result in enhanced anti-tumor activity.
Recombinant cytokines (i.e., IL-15 and IL-2), antibodies blocking inhibitory receptors (i.e., KIR, NKG2A and TIGIT) and agonists delivering signals via CD137, NKG2D and CD16 stand out as the most suitable opportunities.
These agents can be used to potentiate NKcell- mediated antibody-dependent cellular cytotoxicity (ADCC) against antibody-coated tumor cells, offering potential for multiple combinatorial immunotherapy strategies against cancer.
CITATION Curr Opin Immunol. 2017 Feb 22;45:73-81. doi: 10.1016/j.coi.2017.01.003
you maybe interested
The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.
The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.
Learn why we are different from other healthcare centers. Quality, speed, comfort and results.